ABSTRACT
However, “no-option” patients are a heterogeneous group. Myocardial viability identifies two different clinical and prognostic patterns in this population. The first group includes patients with a substantial amount of viable myocardium, in whom angina is the predominant symptom. In these patients, improved myocardial perfusion may relieve symptoms, improve the left ventricular ejection fraction (LVEF), reverse ventricular remodeling,4 and increase survival.5 Conversely, the second group includes patients with limited or no myocardial viability, in whom heart failure symptoms predominate. This group has a poorer response to increased myocardial perfusion.6
